What drugs are being tested in NCT04992026?

Interventions in NCT04992026: robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection, 1.Abiraterone Acetate Tablets, Prednisone Acetate Tablets, Luteinizing Hormone-Releasing Hormone Analog.

What condition does NCT04992026 study?

NCT04992026 studies Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone.

Is NCT04992026 still recruiting?

NCT04992026 is currently completed. Last updated 5 December 2024.

Last reviewed 2024-12-05 · How we verify

NCT04992026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

Completed Phase 2 Last updated 5 December 2024

What this trial tests

Phase 2 trial testing robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection in Prostatectomy in 130 participants. Completed in 2 December 2024.

Timeline

1 January 2021

Primary endpoint
1 December 2024

2 December 2024

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	1 January 2021
Primary completion	1 December 2024
Estimated completion	2 December 2024
Sites	1 location across China

Drugs / interventions tested

robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection
1.Abiraterone Acetate Tablets — full drug profile →
Prednisone Acetate Tablets — full drug profile →
Luteinizing Hormone-Releasing Hormone Analog — full drug profile →

Conditions studied

Prostatectomy — all drugs for Prostatectomy →
Oligometastatic Prostate Cancer — all drugs for Oligometastatic Prostate Cancer →
Abiraterone — all drugs for Abiraterone →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 40 to 75, male only, with Prostatectomy or Oligometastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, controlled, multi-center clinical trial aims to evaluate the efficacy and safety of prostatectomy for castration-Naive oligometastatic prostate cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The current role of precision surgery in oligometastatic prostate cancer.
von Deimling M, Rajwa P, Tilki D, Heidenreich A, et al · · 2022 · cited 11× · PMID 36208497 · DOI 10.1016/j.esmoop.2022.100597
A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions.
Alerasool P, Zhou S, Miller E, Anker J, et al · · 2025 · cited 1× · PMID 39796774 · DOI 10.3390/cancers17010147
A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery.
Wang Y, Zhang S, Huang H, Qiu X, et al · · 2022 · PMID 36713499 · DOI 10.3389/fonc.2022.1059410

Verify or expand the search:

Other recruiting trials for Prostatectomy

Currently open trials in the same condition.

NCT06274047 — PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life i · Phase 3 · recruiting
NCT06982469 — High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy · recruiting
NCT03080116 — Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy · Phase 2 · active not recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04992026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 5 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04992026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing